AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39252617 — intervention group
Group type: EXPERIMENTAL
Intervention: PACMAN (Pre-operative triAge proCedure to streaMline elective surgicAl patieNts)
Number of subjects: 965
Study 39252617 — intervention group
Group type: EXPERIMENTAL
Intervention: PACMAN
Number of subjects: 965
Study 39252617 — intervention group
Group type: COMPARATOR
Intervention: Standard care (evaluation of standard care)
Number of subjects: 965
Study 39252657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (225 mg twice daily)
Number of subjects: 315
Study 39252657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate
Number of subjects: 315
Study 39252657 — intervention group
Group type: COMPARATOR
Intervention: 1.62% topical testosterone gel
Number of subjects: 315
Study 39252657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 315
Study 39252725 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderated hypofractionated online adaptive radiotherapy (MHRT with oART)
Number of subjects: 0
Study 39252725 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study 39252861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 0
Study 39252861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39252865 — intervention group
Group type: EXPERIMENTAL
Intervention: Adebrelimab (20 mg/kg, D1, Q3W) plus chemotherapy (EP/EC) followed by sequential thoracic radiotherapy (TRT)
Number of subjects: 67
Study 39252867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexasodium fytate 7 mg/kg
Number of subjects: 71
Study 39252867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 39252988 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence method for indicating flap trimming
Number of subjects: 10
Study 39252988 — intervention group
Group type: COMPARATOR
Intervention: Indocyanine green fluorescence angiography (ICGFA)
Number of subjects: 10
Study 39253004 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Promotion
Number of subjects: 0
Study 39253004 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-Based Compassion Therapy
Number of subjects: 0
Study 39253004 — intervention group
Group type: COMPARATOR
Intervention: Usual treatments (workshops)
Number of subjects: 0
Study 39253025 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC) intervention, TBI Care, with weekly assessments and an average of 11 out of 12 sessions with a care manager (CM).
Number of subjects: 79
Study 39253025 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC) intervention, TBI Care.
Number of subjects: 79
Study 39253357 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-KH vaccine
Number of subjects: 86
Study 39253357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 39253360 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-triggered rTMS of the ipsilesional M1 (1,200 pulses; 0.33 Hz; 100% RMT)
Number of subjects: 30
Study 39253360 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency rTMS of the contralesional motor cortex (1,200 pulses; 1 Hz; 115% RMT)
Number of subjects: 30
Study 39253712 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT >9.6 ng/L (highest category)
Number of subjects: 708
Study 39253713 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitors prescribed in patients with periprocedural myocardial injury (197 patients, 70%)
Number of subjects: 2083
Study 39253713 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitors prescribed in patients without periprocedural myocardial injury (1,251 patients, 71.2%)
Number of subjects: 2083
Study 39253713 — intervention group
Group type: COMPARATOR
Intervention: Patients without periprocedural myocardial injury
Number of subjects: 2083
Study 39253804 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxocara canis infection (positive serology)
Number of subjects: 986
Study 39253804 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE concentration and eosinophil count
Number of subjects: 986
Study 39253832 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Yoga Intervention
Number of subjects: 0
Study 39253832 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39254129 — intervention group
Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, single treatment of 30 minutes at peak negative pressure of 4.5 to 8 MPa.
Number of subjects: 44
Study 39254129 — intervention group
Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, after optimal therapy settings determined.
Number of subjects: 44
Study 39254129 — intervention group
Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, effectiveness in lower pole stones.
Number of subjects: 44
Study 39254129 — intervention group
Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, effectiveness in distal ureteral stones.
Number of subjects: 44
Study 39254129 — intervention group
Group type: EXPERIMENTAL
Intervention: Break Wave lithotripsy (BWL) device, safety outcomes.
Number of subjects: 44
Study 39254220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 661
Study 39254220 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased cortical cerebral blood flow (CBF)
Number of subjects: 661
Study 39254220 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased amyloid burden
Number of subjects: 661
Study 39254220 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL CBF and amyloid
Number of subjects: 661
Study 39254220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower regional gray matter CBF
Number of subjects: 661
Study 39254446 — intervention group
Group type: EXPERIMENTAL
Intervention: nnU-Net model for lesion segmentation and categorization using classic radiomics and autoencoder features
Number of subjects: 1241
Study 39254446 — intervention group
Group type: COMPARATOR
Intervention: Histopathologically or follow-up-confirmed diagnosis
Number of subjects: 1241
Study 39254458 — intervention group
Group type: EXPERIMENTAL
Intervention: US shear-wave elastography (SWE)
Number of subjects: 0
Study 39254458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration-controlled transient elastography (VCTE)
Number of subjects: 0
Study 39254466 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy for 24 hours per day
Number of subjects: 241
Study 39254466 — intervention group
Group type: COMPARATOR
Intervention: Long-term oxygen therapy for 15 hours per day
Number of subjects: 241
Study 39254489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel (CP)
Number of subjects: 154
Study 39254489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab plus CP
Number of subjects: 154
Study 39254622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 112
Study 39254622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (transitioned to Mavacamten from week 16 to week 56)
Number of subjects: 112
Study 39254740 — intervention group
Group type: EXPERIMENTAL
Intervention: Efsitora
Number of subjects: 928
Study 39254740 — intervention group
Group type: COMPARATOR
Intervention: Degludec
Number of subjects: 928
Study 39254777 — intervention group
Group type: COMPARATOR
Intervention: Online gambling
Number of subjects: 237
Study 39254777 — intervention group
Group type: COMPARATOR
Intervention: Offline gambling
Number of subjects: 237
Study 39254777 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived self-efficacy
Number of subjects: 237
Study 39254777 — intervention group
Group type: EXPERIMENTAL
Intervention: No history of mood disorders
Number of subjects: 237
Study 39254777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower level of sensation seeking
Number of subjects: 237
Study 39254890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg or 50 mg once daily (with or without an initial 4-week 200-mg daily loading dose)
Number of subjects: 522
Study 39255055 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 597
Study 39255055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 597
Study 39255055 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 597
Study 39255440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 39255440 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib
Number of subjects: 0
Study 39255440 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 39255440 — intervention group
Group type: COMPARATOR
Intervention: Savolitinib
Number of subjects: 0
Study 39255444 — intervention group
Group type: EXPERIMENTAL
Intervention: B7-H3 chimeric antigen receptor (CAR) T cells at dose level 1 (DL1) 0.5 × 10^6 cells
Number of subjects: 16
Study 39255444 — intervention group
Group type: EXPERIMENTAL
Intervention: B7-H3 chimeric antigen receptor (CAR) T cells
Number of subjects: 16
Study 39255484 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based behavioral intervention (SBI) consisting of a smart water bottle and smartphone app that alerts patients to empty their bladder and drink a personalized volume goal 1.25 hours before RT.
Number of subjects: 36
Study 39255484 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based behavioral intervention (SBI) consisting of a smart water bottle and smartphone app.
Number of subjects: 36
Study 39255534 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days
Number of subjects: 12
Study 39255587 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 100 μg
Number of subjects: 25
Study 39255587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 39255991 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5475 32 µg
Number of subjects: 168
Study 39255991 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5475 100 µg
Number of subjects: 168
Study 39255991 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5475 380 µg
Number of subjects: 168
Study 39255991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 39255990 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1291583 5 mg
Number of subjects: 322
Study 39255990 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1291583 2.5 mg
Number of subjects: 322
Study 39255990 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1291583 1 mg
Number of subjects: 322
Study 39255990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 39256281 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic taste (MT) experienced by patients during treatment
Number of subjects: 44
Study 39256281 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with metallic taste (MT)
Number of subjects: 44
Study 39256291 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg/tramadol 50 mg (QD for 7 days)
Number of subjects: 124
Study 39256291 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 975 mg/tramadol 112.5 mg (TID for 7 days)
Number of subjects: 124
Study 39256297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-18 fluorodeoxyglucose (FDG) PET/CT imaging
Number of subjects: 23
Study 39256297 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study 39256350 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8-RLBP1 gene therapy
Number of subjects: 12
Study 39256427 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 434
Study 39256427 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent (DES)
Number of subjects: 434
Study 39256512 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI-28592
Number of subjects: 1
Study 39256658 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-oriented intervention for family members of patients with TBI
Number of subjects: 73
Study 39256658 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 73
Study 39256675 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior quadratus lumborum block (QLB3)
Number of subjects: 96
Study 39256675 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 96
Study 39256675 — intervention group
Group type: COMPARATOR
Intervention: Control (no block)
Number of subjects: 96
Study 39256711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mpox Stigma Scale (MSS)
Number of subjects: 330
Study 39256711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mpox Knowledge Scale (MKS)
Number of subjects: 330
Study 39256781 — intervention group
Group type: EXPERIMENTAL
Intervention: GAmAge (newborn DNA methylation age)
Number of subjects: 831
Study 39256835 — intervention group
Group type: EXPERIMENTAL
Intervention: FFA levels ≥ 580 µmol/L
Number of subjects: 10395
Study 39256835 — intervention group
Group type: EXPERIMENTAL
Intervention: FFA levels < 310 µmol/L
Number of subjects: 10395
Study 39256847 — intervention group
Group type: EXPERIMENTAL
Intervention: GONB + PRF
Number of subjects: 32
Study 39256847 — intervention group
Group type: COMPARATOR
Intervention: GONB
Number of subjects: 32
Study 39257031 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital stories created by children
Number of subjects: 0
Study 39257218 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group mammography video discussion (SMVD)
Number of subjects: 956
Study 39257218 — intervention group
Group type: COMPARATOR
Intervention: Video-only group
Number of subjects: 956
Study 39257218 — intervention group
Group type: EXPERIMENTAL
Intervention: SMVD attendees
Number of subjects: 956
Study 39257218 — intervention group
Group type: EXPERIMENTAL
Intervention: SMVD nonattendees
Number of subjects: 956
Study 39257478 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds (2 oz/d)
Number of subjects: 26
Study 39257478 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric pretzel (CONTROL)
Number of subjects: 26
Study 39257857 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized exercise program (PEP) intervention for fatigue
Number of subjects: 337
Study 39257857 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 337
Study 39257986 — intervention group
Group type: EXPERIMENTAL
Intervention: CASCADE approach
Number of subjects: 27
Study 39258362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) using a variable-loop catheter with electroanatomic mapping system
Number of subjects: 277
Study 39258362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 277
Study 39258519 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated peritoneal dialysis (APD)
Number of subjects: 131
Study 39258519 — intervention group
Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 131
Study 39258531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alteplase
Number of subjects: 4410
Study 39258531 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose intravenous alteplase
Number of subjects: 4410
Study 39258531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 4410
Study 39258531 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering
Number of subjects: 4410
Study 39258729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study 39258729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (started in the extension study)
Number of subjects: 0
Study 39258729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39258838 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg once daily)
Number of subjects: 82
Study 39258838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 39258961 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity acute exercise (45-55% HRR)
Number of subjects: 60
Study 39258961 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity acute exercise (65-75% HRR)
Number of subjects: 60
Study 39258976 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin administered after chemotherapy and immunotherapy
Number of subjects: 0
Study 39258976 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Number of subjects: 0
Study 39259239 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC-HIV
Number of subjects: 13894
Study 39259239 — intervention group
Group type: COMPARATOR
Intervention: No EPIC-HIV
Number of subjects: 13894
Study 39259239 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC-HIV 2
Number of subjects: 13894
Study 39259239 — intervention group
Group type: COMPARATOR
Intervention: EPIC-HIV vs No EPIC-HIV
Number of subjects: 13894
Study 39259241 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer League (SL) intervention
Number of subjects: 1193
Study 39259241 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer League followed by Vocational Training (SL/VT) intervention
Number of subjects: 1193
Study 39259241 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 1193
Study 39259284 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance Confocal Microscopy (RCM)
Number of subjects: 326
Study 39259284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy plus clinical examination
Number of subjects: 326
Study 39259284 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination alone
Number of subjects: 326
Study 39259383 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training (MulTI)
Number of subjects: 27
Study 39259383 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 27
Study 39259397 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity free-weight resistance training to failure
Number of subjects: 41
Study 39259541 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (1 ng/kg/min for 72 hours)
Number of subjects: 279
Study 39259541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 39259541 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 279
Study 39259542 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) - 1-time subcutaneous lumbar saline injection presented as placebo
Number of subjects: 101
Study 39259542 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 101
Study 39259550 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy for inpatients (up to 4 individual sessions)
Number of subjects: 200
Study 39259550 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study 39259550 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy for inpatients
Number of subjects: 200
Study 39259563 — intervention group
Group type: EXPERIMENTAL
Intervention: Video visit early palliative care
Number of subjects: 1250
Study 39259563 — intervention group
Group type: COMPARATOR
Intervention: In-person early palliative care
Number of subjects: 1250
Study 39259562 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828), oral administration, intermittent dosing schedule
Number of subjects: 0
Study 39259562 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828), oral administration
Number of subjects: 0
Study 39259562 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Number of subjects: 0
Study 39259927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Pertuzumab and Trastuzumab
Number of subjects: 0
Study 39259927 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39259959 — intervention group
Group type: EXPERIMENTAL
Intervention: VR motor-cognitive training (VRMCT) - 16 one-hour training sessions delivered twice per week for 8 weeks.
Number of subjects: 293
Study 39259959 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by older adult community centers (control group).
Number of subjects: 293
Study 39259961 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 period HRU
Number of subjects: 68822
Study 39259961 — intervention group
Group type: COMPARATOR
Intervention: Pre-COVID-19 period HRU
Number of subjects: 68822
Study 39260076 — intervention group
Group type: EXPERIMENTAL
Intervention: suvorexant (10-20 mg)
Number of subjects: 34
Study 39260076 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 39260086 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of social support (measured using OARS Medical Social Support score)
Number of subjects: 347
Study 39260086 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantity of social support (number of close friends and relatives)
Number of subjects: 347
Study 39260392 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (laxative regimens)
Number of subjects: 67
Study 39260392 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (colostomy, segmental resection, hemicolectomy, subtotal colectomy)
Number of subjects: 67
Study 39260415 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal fetal fraction (≥10th percentile)
Number of subjects: 1041
Study 39260415 — intervention group
Group type: COMPARATOR
Intervention: Low fetal fraction (<5%)
Number of subjects: 1041
Study 39260415 — intervention group
Group type: COMPARATOR
Intervention: High fetal fraction (>95%)
Number of subjects: 1041
Study 39260540 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant (45-mg twice daily)
Number of subjects: 187
Study 39260540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 39260785 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin Angiotensin system inhibitors (RASi) therapy
Number of subjects: 2453
Study 39260823 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychedelic-assisted therapy using classical psychedelics (psilocybin, LSD)
Number of subjects: 149
Study 39260823 — intervention group
Group type: COMPARATOR
Intervention: Psychedelic-assisted therapy using MDMA
Number of subjects: 149